These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29762386)

  • 1. Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.
    Kovanda LL; Walsh TJ; Benjamin DK; Arrieta A; Kaufman DA; Smith PB; Manzoni P; Desai AV; Kaibara A; Bonate PL; Hope WW
    Pediatr Infect Dis J; 2018 Jun; 37(6):580-585. PubMed ID: 29762386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.
    Benjamin DK; Kaufman DA; Hope WW; Smith PB; Arrieta A; Manzoni P; Kovanda LL; Lademacher C; Isaacson B; Jednachowski D; Wu C; Kaibara A; Walsh TJ
    Pediatr Infect Dis J; 2018 Oct; 37(10):992-998. PubMed ID: 29596222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of micafungin in neonates and young infants.
    Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
    Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
    Gumbo T
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Zijlstra JG; van der Werf TS; Alffenaar JWC; Touw DJ
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0111322. PubMed ID: 36377940
    [No Abstract]   [Full Text] [Related]  

  • 7. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
    Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
    Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age.
    Abdel-Haq N; Smith SM; Asmar BI
    Expert Rev Anti Infect Ther; 2022 Apr; 20(4):493-505. PubMed ID: 34882043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
    Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
    J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
    Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.
    Leroux S; Jacqz-Aigrain E; Elie V; Legrand F; Barin-Le Guellec C; Aurich B; Biran V; Dusang B; Goudjil S; Coopman S; Garcia Sanchez R; Zhao W; Manzoni P;
    Br J Clin Pharmacol; 2018 Sep; 84(9):1989-1999. PubMed ID: 29744900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Regulatory Review Approach for Evaluation of Micafungin for Treatment of Neonatal Candidiasis.
    Taormina G; Gopinath R; Moore J; Yasinskaya Y; Colangelo P; Reynolds K; Nambiar S
    Clin Infect Dis; 2021 Dec; 73(12):2335-2340. PubMed ID: 33458754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
    Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
    Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.
    Wasmann RE; Muilwijk EW; Burger DM; Verweij PE; Knibbe CA; Brüggemann RJ
    Clin Pharmacokinet; 2018 Mar; 57(3):267-286. PubMed ID: 28791666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
    Spec A; Pullman J; Thompson GR; Powderly WG; Tobin EH; Vazquez J; Wring SA; Angulo D; Helou S; Pappas PG;
    J Antimicrob Chemother; 2019 Oct; 74(10):3056-3062. PubMed ID: 31304536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.
    Rivera-Chaparro ND; Ericson J; Wu H; Smith PB; Clark RH; Benjamin DK; Cohen-Wolkowiez M; Greenberg RG
    Pediatr Infect Dis J; 2019 Feb; 38(2):e26-e28. PubMed ID: 29601453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections.
    Garbez N; Mbatchi L; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230720. PubMed ID: 33846133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
    Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
    Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.